Figure 6.

Ex vivo and in vivo application of UNC10201652. Statistical differences are annotated as follows: *, p = 0.001. A, fecal samples from 11 mice were incubated with E1-3G in the presence and absence of UNC10201652. Fecal samples incubated with inhibitor show decreased activity. B, fecal samples from 11 mice were incubated with E2-17G in the presence and absence of UNC10201652. Fecal samples incubated with inhibitor show decreased activity. C, lesion size of PyMT-treated mouse model of breast cancer. Mice treated with UNC10201652 show no difference in lesion size compared with control mice. Data are presented as the average of 3 biological replicates ± SEM.